Botanix Pharmaceuticals has announced encouraging results from a small pilot study of its BTX 1204A synthetic CBD formulation in canines with Atopic Dermatitis (AD).

Four dogs, screened for moderate to severe dermatitis, were treated topically with BTX 1204A over a 28-day period, resulting in a significant improvement in their condition.

Canine AD is clinically and immunologically similar to human AD, meaning the results are useful in informing the progression of further human studies.

Botanix is now advancing plans for a larger BTX 1204A proof of concept canine study in Australia, which aims to confirm and expand safety and efficacy data.

The company will then pursue opportunities to partner in animal health markets and progress towards a Phase 2b study for AD in humans in H1 2022.